|
|
|
|
|
 |
|
IBP-M2T
Is a monoclonal antibody with an established global annual sales of $6 billion. This humanized MAB binds to teh extracellular segment of the HER2/ neu receptor leading to disruption of receptor dimerization and signaling through the downstream PI3K cascade. IBP-M2T is used for treatment of breast cancer patients who are HERs/ neu. This product is out-licenced to Lupin Ltd. |
|
|
|
|
|
|
|
|
|
|
|
IBP-H1P
Is a hormone that acts to increase the concentration of calcium in the blood by the body. Acting upon three parts of the hormone receptor leading to disruption of receptor dimerization and signaling through the downstream PI3K cascade. The administration of IBP-H1P teriparatide stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over IBP-H2F: binds to the follicle stimulating hormone receptor, which is a G-coupled transmembrane. receptor. Binding to its receptor induces phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells. This recombinant hormone is used in female infertility treatment. |
|
|
|
|
|
|
|
|
|
|
|
IBP-E1T
For management of acute myocardial infarction, acute ischemic stroke and for lysis of acute pulmonary emboli Binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin It also produces limited conversion of plasminogen in the absence of fibrin IBP-E1T is ready for animal toxicology studies. |
|
|
|
|
|
|
|
|
|
|
|
IBP-C1G
IBP-C1G binds to the colony stimilating factor receptor. As a colony stimulating factor analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils Haematopoietic growth factor stimulates the bone marrow to produce more white blood cells IBP-C1G is ready for animal toxicology studies. |
|
|
|
|
|
|
|
|
|
|
|
IBP-M3C
IBP-M3C is an IgG1 monoclonal antibody (MAb) that binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. prevents downstream signal transduction and cellular responses Blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis. IBP-M3c is used For treatment of metastatic colorectal cancer |
|
|
|
|
|
|
|
|
|
|
|
IBp-C21
IBP-C21Binds directly to the type II IFNGR1, leading to a complex of IFNGR1 and IFNGR2. Many components of the antigen presentation pathways are up-regulated, potent activator of macrophages, it has antiproliferative effects,antiviral and antitumor effects. IBP-C2I is used For treatment of Chronic granulomatous disease, Osteopetrosis |
|
|
|
|
|
|
|
|
|
|
|
IBP-C31
IBP-C31Binds directly to the type I IFNAR1 and IFNAR2c, which upon dimerization activates tyrosine kinases. Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens it has antiproliferative effects,antiviral and antitumor effects. IBP-C3I is For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma |
|
|
|
|
|
|
|
|
|
|
|
IBP-C51
IBP-C5I binds to the Interleukin-1 type I receptor (IL-1RI), inhibiting the action of elevated levels IL-1 leading to cartilage degradation and bone resorption blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor. Antiinflammatory, antirheumatic,Immunomodulatory agent. IBP-C5I is used For the treatment of adult rheumatoid arthritis. |
|
|
|
|
|
|
|
|
|
|
|
IBP-C6G
IBP-C6G binds to the CSF2R and stimulates a signal transduction pathway which to the production of hemopoietic cells and neutrophils stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells Antiinfective, antineoplastic, Immunomodulatory agent. IBP-C6G is used For the treatment of cancer and bone marrow transplant. |
|
|
|
|
|
|
|
|
|
|
|
IBP-H2F
IBP-E1T binds to the follicle stimulating hormone receptor, which is a G-coupled transmembrane receptor. Binding to its receptor induces phosphorylation and activation of the PI3 receptor. Binding to its receptor induces phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/ maturation functions in cells. This recombinant hormone is used in female infertility treatment. |
|
|
|
|
|
|
|
|
|
|
|
IBP-M4I
IBP-M4I binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors neutralizes the biological activity of TNFa by binding with high affinity Immunomodulatory and immunosuppressive agent. IBP-M4I is used For treatment of Crohn's disease, psoriasis, rheumatoid arthitis and ankylosing spondylitis |
|
|
|
|
|
|
|
|
|
|
|
IBp-H3L
Binds to the luteinizing hormone receptor which then activates adenylate cylcase through G protein mediation. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes. IBP-H2F is used in treatment of female infertility. |
|
|
|
|
|
|
|
|
|
|
|
IBP-H4H
Binds to the follicle stimulating hormone receptor which results in ovulation in teh absence of sufficient endogenous luteinizing hormone stimulates late follicular stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle Fertility agent, gonadotropins. IBP-H4H is used For the treatment of female infertility |
|
|
|
|
|
|
